Inhaled hypertonic saline delivered by a heated nasal cannula

• US 9,987,443 B2
• Filed: 08/08/2016
• Issued: 06/05/2018
• Est. Priority Date: 10/10/2007
• Status: Active Grant

• Current Assignee: Parion Sciences, Inc.
• Original Assignee: Parion Sciences, Inc.
• Inventors: Boucher, Richard C., Johnson, Michael Ross
• Primary Examiner(s): Wax, Robert A
• Assistant Examiner(s): Mercier, Melissa S
• Application Number:
  US15/230,839
• Publication Number:
  US 20170151396A1
• Time in Patent Office: 666 Days
• Field of Search: None
• CPC Class Codes: A61M 11/001 Particle size control
• CPC Class Codes: A61M 11/02 operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised sprayers for horticulture A01G, A01H; killing insects A01M; air humidifying by nozzles F24F6/14, F24F6/18; cooling by spraying F28B, F28C
• CPC Class Codes: A61M 15/08 Inhaling devices inserted into the nose
• CPC Class Codes: A61M 16/0666 Nasal cannulas or tubing devices for improving normal breathing through the nose A61F5/08; nose filters A62B23/06; outside holding devices A61M25/02
• CPC Class Codes: A61M 16/0875 Connecting tubes
• CPC Class Codes: A61M 16/1075 by influencing the temperature A61M16/1045 takes precedence
• CPC Class Codes: A61M 16/1095 in the connecting tubes
• CPC Class Codes: A61M 16/14 by mixing different fluids, one of them being in a liquid phase
• CPC Class Codes: A61M 16/18 Vaporising devices for anaesthetic preparations
• CPC Class Codes: A61M 2202/0488 Surfactant, e.g. for the lung
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants

Abstract

The invention described herein is directed to method of treating chronic obstructive pulmonary disease, comprising administering an effective amount of an osmolyte by at least one nasal cannula to a subject in need thereof. Also provided is a nasal cannula system for delivering an osmolyte, comprising a nebulizer and tubing having two ends, where the first end of the tubing is connected to the nebulizer and the second end of the tubing is tapered to fit in the nostril of a subject.

Claims

1. An apparatus, comprising:

a nasal cannula assembly configured to receive at a first end portion a flow of aerosolized medicament having a particle size of about one micron to about five microns MMD,

the nasal cannula assembly configured to convey from the first end portion to a second end portion the flow of aerosolized medicament to deliver the flow of aerosolized medicament transnasally to a subject without accumulation of liquid droplets.

2. The apparatus of claim 1, wherein a length from the first end portion of the nasal cannula assembly to the second end portion of the nasal cannula assembly is about two meters to about four meters.

3. The apparatus of claim 1, wherein the nasal cannula assembly is configured to deliver the aerosolized medicament to the subject over a period of 23 to 80 minutes while limiting accumulation of liquid droplets from the flow of aerosolized medicament.

4. The apparatus of claim 1, wherein at least a portion of the nasal cannula assembly has an inner diameter of about three millimeters to about five millimeters.

5. The apparatus of claim 1, wherein the nasal cannula assembly is configured to convey the aerosolized medicament continuously over a period of hours.

6. The apparatus of claim 1, further comprising:

an aerosol preparation mechanism configured to receive a flow of gas at a first port, the aerosol preparation mechanism configured to convey the flow of aerosolized medicament from a second port and to the first end portion of the nasal cannula assembly.

7. An apparatus, comprising:

a nasal cannula assembly having a tube portion and a face piece portion, the tube portion configured to be operably coupled to an aerosol preparation mechanism, the face piece portion configured to be removably coupled to a nostril of a subject,

the nasal cannula assembly configured to receive, at the tube portion and from the aerosol preparation mechanism, a flow of aerosolized medicament including respirable particles, the nasal cannula assembly configured to convey via the face piece portion the aerosolized medicament to the nostril of the subject, at least a portion of the nasal cannula assembly having an inner diameter of about three millimeters to about five millimeters.

8. The apparatus of claim 7, wherein a length from a first end portion of the nasal cannula assembly to a second end portion of the nasal cannula assembly is about two meters to about four meters.

9. The apparatus of claim 7, wherein the nasal cannula assembly is configured to deliver the aerosolized medicament to the subject over a period of 23 to 80 minutes while limiting accumulation of liquid droplets from the flow of aerosolized medicament.

10. The apparatus of claim 7, wherein the nasal cannula assembly is configured to convey the aerosolized medicament continuously over a period of hours.

11. The apparatus of claim 7, further comprising:

an aerosol preparation mechanism configured to receive a flow of gas at a first port, the aerosol preparation mechanism configured to convey the flow of aerosolized medicament from a second port and to the tube portion of the nasal cannula assembly.

12. An apparatus, comprising:

a nasal cannula assembly having a tube portion and a face piece portion, the tube portion configured to be operably coupled to an aerosol preparation mechanism, the face piece portion configured to be removably coupled to a nostril of a subject,

the nasal cannula assembly configured to receive, at the tube portion and from the aerosol preparation mechanism, a flow of aerosolized medicament including respirable particles, the nasal cannula assembly configured to convey via the face piece portion the aerosolized medicament to the nostril of the subject, a length from a first end portion of the nasal cannula assembly to a second end portion of the nasal cannula assembly being about two meters to about four meters.

13. The apparatus of claim 12, wherein the nasal cannula assembly is configured to deliver the aerosolized medicament to the subject over a period of 23 to 80 minutes while limiting accumulation of liquid droplets from the flow of aerosolized medicament.

14. The apparatus of claim 12, wherein at least a portion of the nasal cannula assembly has an inner diameter of about three millimeters to about five millimeters.

15. The apparatus of claim 12, wherein the nasal cannula assembly is configured to convey the aerosolized medicament continuously over a period of hours.

16. The apparatus of claim 12, further comprising:

an aerosol preparation mechanism configured to receive a flow of gas at a first port, the aerosol preparation mechanism configured to convey the flow of aerosolized medicament from a second port and to the tube portion of the nasal cannula assembly.

17. The apparatus of claim 12, wherein the aerosolized medicament includes a hypertonic saline.